Sustained Improvement in Health-Related Quality of Life in Transplant-Ineligible Newly Diagnosed Multiple Myeloma Treated With Daratumumab, Lenalidomide, and Dexamethasone: MAIA Final Analysis of Patient-Reported Outcomes.
Perrot A., Facon T., Plesner T., Usmani SZ., Kumar S., Bahlis NJ., Hulin C., Orlowski RZ., Nahi H., Mollee P., Ramasamy K., Roussel M., Jaccard A., Delforge M., Karlin L., Arnulf B., Chari A., Wang G., Gupta-Werner N., Kaila S., Pei H., Matt K., Gries KS., Carson R., Borgsten F., Weisel K.
OBJECTIVES: This final post hoc analysis evaluated patient-reported outcomes from the Phase 3 MAIA study of daratumumab, lenalidomide, and dexamethasone (D-Rd) versus lenalidomide and dexamethasone (Rd) after median 64.5-month follow-up in transplant-ineligible patients with newly diagnosed multiple myeloma (NDMM), including patient subgroups. METHODS: Key scales from the EORTC QLQ-C30 (global health status [GHS], physical functioning, pain, and fatigue) were assessed. Scores were evaluated every 3 months for 1 year, then every 6 months until disease progression. RESULTS: The intent-to-treat population (n = 737) included 46.3% frail, 35.4% 70 to